8-K - RenovoRx, Inc. | StockGist

AI Analysis

AI-generated analysis. Always verify with the original filing.

RenovoRx, Inc. appointed Dr. Ramtin Agah to the newly created position of Executive Chairman, effective February 27, 2026, while he continues as Chief Medical Officer. The company entered into an amended employment agreement with Dr. Agah, which includes an annual base salary of $450,000 and eligibility for an annual discretionary bonus of up to 40% of his base salary.

Key Takeaways

1Dr. Ramtin Agah was appointed to the newly created position of Executive Chairman, effective February 27, 2026, while continuing as Chief Medical Officer.

2The appointment was formalized by the board of directors on March 24, 2026.

3Dr. Agah's amended employment agreement includes an annualized base salary of $450,000, based on working a minimum of 30 hours per week.

4Dr. Agah is eligible for an annual discretionary bonus of up to 40% of his annualized base salary, with the first bonus payable in 2027 for 2026 performance.

5Dr. Agah will be eligible to receive annual grants of options to purchase shares of the company's common stock and other compensatory awards as determined by the Compensation Committee.

6The employment agreement amends, restates, and replaces the prior Consulting Agreement dated January 1, 2018, while the Amended and Restated Change in Control and Severance Agreement dated November 10, 2025, remains in effect.

Current Report Details

Event Type

Management Change

Exhibits Only

Disclosure

Mandatory

Variant

8-K

Items Reported

5.02

. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangement of Certain Officers. On March 24,

Management Change

$450000.00B

9.01

. Financial Statements and Exhibits. (d) Exhibits. No. Exhibit 10.1+ Agah Offer Letter, dated March 24, 2026 and effective February 27, 2026, by and between the

Exhibits Only

Executive & Director Changes

Ramtin Agah, M.D.

Executive Chairman and Chief Medical Officer

Appointment

Effective: 2026-02-27

Newly created position

Exhibits (2)

10.1

EX-10.1

8-K